Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation

Abstract

Despite the advances in immunosuppressive medications, antibody-mediated rejection (AMR) continues to be a major cause of kidney allograft failure and remains a barrier to improving long-term allograft survival. Recently, there have been significant advances in the understanding of the pathophysiological process of AMR, along with the development of new therapeutic options. Additionally, surveillance protocols with donor-derived cell-free DNA and gene profile testing have been established, leading to the early detection of AMR. A multitude of clinical trials are ongoing, opening numerous opportunities for improving outcome in kidney transplant recipients. In this brief review, we discuss the emerging therapies for managing both active and chronic active AMR and highlight the ongoing clinical trials.

New treatment for antibody-mediated rejection: interleukin-6 inhibitors

“…However, due to infectious complications impacting some participants, the dosage was reduced to 12.5 mg in later studies. These findings underscore the importance of establishing appropriate entry criteria and the necessity for vigilant monitoring when administering clazakizumab [ 1 , 19 – 21 ].…”